Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Drop in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 24,740 shares, a decrease of 25.3% from the December 31st total of 33,109 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 181,623 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 181,623 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, BTIG Research reduced their price objective on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $1.50.

Xtant Medical Trading Up 1.0%

Shares of Xtant Medical stock traded up $0.01 during trading hours on Tuesday, reaching $0.61. 132,997 shares of the company’s stock were exchanged, compared to its average volume of 177,547. Xtant Medical has a 52-week low of $0.34 and a 52-week high of $0.95. The company has a fifty day moving average of $0.69 and a 200-day moving average of $0.68. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $84.98 million, a price-to-earnings ratio of 60.76 and a beta of -0.04.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Monday, November 10th. The medical device company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $32.70 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XTNT. Vanguard Group Inc. raised its stake in shares of Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after acquiring an additional 104,159 shares during the period. Mink Brook Asset Management LLC raised its position in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares during the period. AWM Investment Company Inc. purchased a new position in Xtant Medical in the second quarter valued at about $4,875,000. Nantahala Capital Management LLC lifted its stake in shares of Xtant Medical by 500.3% during the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after purchasing an additional 57,000,000 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Xtant Medical in the second quarter worth about $26,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.